Prescription drug use and subsequent morbidity and mortality
Project
|Last update
The project will provide information on how medicines are used in the general population.
Summary
Clinical trials of drugs have restrictions that limit the knowledge of new drugs at the time of marketing: relatively few people in a limited period of time have been exposed to the drug. Signs of adverse reactions should therefore be evaluated after the drugs have been taken in normal use by the population using epidemiological studies in which systematic bias is attempted to be avoided. Knowledge of how drugs are used in the population is also important. The project will provide information on how medicines are used in the general population - and on effects and side effects - by linking the Norwegian Prescription Database with the Cause of Death Register, the Patient Register, the Cancer Registry, health surveys (three counties, 40-year surveys 1985-1999 and CONOR 1994-2003) and socioeconomic information from Statistics Norway. The following specific issues are included:
a) Use of the insulin analogue Lantus and cancer risk.
b) Medicine use and diagnoses for ADHD.
c) Use of psychiatric drugs among children and adolescents.
d) Medical prevention of stroke in atrial fibrillation.
e) Drug treatment before and after hospital admissions for asthma.
f) The connection between the use of sedative medicine, sleep medicine, cancer and mortality.
g) Prescription drug use among cancer survivors.
h) Prescription of drugs for and mortality of cardiovascular disease
i) Sleep problems, hypnosis and later ADHD.
Project leader
Vidar Hjellvik, Norwegian Institute of Public Health
Project participants
Vidar Hjellvik, Physical Health and Ageing, Norwegian Institute of Public Health
Zoltan Thinsz, Karolinska Institutet
Peter Vestergaard, Aalborg University
Morten Andersen, Karolinska Institutet
Matti Siivola, University of Helsinki
Mark C.H. De Groot, Utrecht University
Marjanka K. Schmidt, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Jari Haukka, University of Helsinki
Anna But, University of Helsinki
Per Minor Magnus, Centre for Fertility and Health, Norwegian Institute of Public Health
Tone Bjørge, Department of Global Public Health and Primary Care, University of Bergen
Sara Ghaderi, Department of Global Public Health and Primary Care, University of Bergen
Anders Engeland, Physical Health and Ageing, Norwegian Institute of Public Health
Lars Jøran Kjerpeseth, Physical Health and Ageing, Norwegian Institute of Public Health
Marte Handal, Mental Disorders, Norwegian Institute of Public Health
Svetlana Ondrasova Skurtveit, Mental Disorders, Norwegian Institute of Public Health
Ingeborg Hartz, Avd Forskning, Innlandet Hospital Trust
Eva Skovlund, Department of Public Health and Nursing, Norwegian University of Science and Technology
Jon Marius Grasto Wickmann, Health Studies, Norwegian Institute of Public Health
Øystein Karlstad, Physical Health and Ageing, Norwegian Institute of Public Health
Randi Marie Selmer, Physical Health and Ageing, Norwegian Institute of Public Health
Kari Furu, Physical Health and Ageing, Norwegian Institute of Public Health
Inger Johanne Landsjøåsen Bakken, Centre for Fertility and Health, Norwegian Institute of Public Health
Helena Niemi Eide, Infection Control and Preparedness, Norwegian Institute of Public Health
Mariam Anjum, Vestre Viken Hospital Trust
Inger Ariansen, Physical Health and Ageing, Norwegian Institute of Public Health
Start
01.02.2010
End
31.01.2026
Status
Active
Approvals
Regional committees for medical and health research ethics
Project owner/ Project manager
Norwegian Institute of Public Health